Last reviewed · How we verify
NCT07248956
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Phase 2 trial testing Finolizumab in Hypopharyngeal Carcinoma in 116 participants. Currently enrolling.
30 November 2027
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 116 |
| Start date | 22 December 2025 |
| Primary completion | 30 November 2027 |
| Estimated completion | 30 December 2029 |
| Sites | 7 locations across China |
Drugs / interventions tested
- Finolizumab — full drug profile →
- Albumin-Bound Paclitaxel /nab-Paclitaxel — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
- Definitive radiotherapy
- Surgery with postoperative radiotherapy or chemoradiotherapy.
Conditions studied
- Hypopharyngeal Carcinoma — all drugs for Hypopharyngeal Carcinoma →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Adults 18 to 75, any sex, with Hypopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, randomized controlled, prospective clinical study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07248956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypopharyngeal Carcinoma
Currently open trials in the same condition.
- NCT06761937 — Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients · Phase 1 · recruiting
- NCT07295561 — Salvage Surgery in Recurrent Hypopharyngeal Carcinoma: an Observational Single-institutional Study From 1998 · active not recruiting
- NCT05075980 — Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study · Phase 2 · active not recruiting
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07248956 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07248956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing